LifeVantage Corporation

NasdaqCM:LFVN Stock Report

Market Cap: US$79.4m

LifeVantage Future Growth

Future criteria checks 0/6

LifeVantage's revenue and earnings are forecast to decline at 6.4% and 10.7% per annum respectively while EPS is expected to decline by 10.8% per annum.

Key information

-10.7%

Earnings growth rate

-10.81%

EPS growth rate

Personal Products earnings growth28.3%
Revenue growth rate-6.4%
Future return on equityn/a
Analyst coverage

Low

Last updated13 May 2026

Recent future growth updates

Recent updates

Narrative Update • Jun 24

LFVN: Downgrade And Softer Guidance Will Set Up Portugal Expansion Upside

Analysts have trimmed their price target on LifeVantage to $7.00, reflecting a modestly higher discount rate and slightly adjusted P/E assumptions following the latest downgrade in Street research. What’s in the News for LifeVantage LifeVantage updated earnings guidance for the fiscal year ending June 30, 2026, indicating that fiscal 2026 revenue is expected to be close to the lower end of the previously issued guidance range.
Narrative Update • Jun 08

LFVN: Downgrade And Softer Guidance Will Limit Portugal Expansion Support

Analysts have reduced their fair value estimate for LifeVantage after a recent downgrade in Street research coverage, reflecting a slightly lower discount rate and modestly adjusted expectations for revenue trends, profit margins, and future P/E multiples. What's in the News LifeVantage updated guidance for the fiscal year ending June 30, 2026, and now expects revenue to be close to the lower end of its previously issued range.
Narrative Update • May 17

LFVN: Reset Expectations And Portugal Expansion Will Support Future Upside Potential

Analysts cut their price target on LifeVantage from $8 to $7, reflecting a lower fair value estimate, softer profit margin assumptions, and a higher future P/E, following the recent downgrade highlighted in Street research. Analyst Commentary Recent Street commentary points to a more cautious stance on LifeVantage, with the lower price target tied to reassessed earnings power and valuation assumptions following the downgrade.
Narrative Update • May 01

LFVN: Share Repurchases And Reset Expectations Will Support Future Upside Potential

Analysts have trimmed their price target on LifeVantage by $7, reflecting updated views on the company’s fair value and earnings power following recent research. Analyst Commentary Analysts cutting the target price by $7 signals a reset in expectations around what they see as a fair value for LifeVantage, given recent research on the company’s earnings power and execution risks.
Narrative Update • Apr 17

LFVN: Share Repurchases And Portugal Expansion Will Support Future Upside Potential

Analysts have reduced their price target on LifeVantage by $7, citing updated assumptions around discount rates, revenue trends, profit margins, and expected future P/E multiples. Analyst Commentary Analysts link the lower price target to updated views on discount rates, revenue trends, profit margins, and expected future P/E multiples, which together affect how much investors may be willing to pay for LifeVantage shares.
Narrative Update • Apr 02

LFVN: Share Repurchases And Margin Discipline Will Support Future Upside Potential

Analysts have reduced their price target on LifeVantage by $7, citing updated assumptions around discount rates, long term revenue trends, profit margins, and future P/E expectations. Analyst Commentary Analysts cutting the price target by $7 are updating their framework for discount rates, long term revenue trends, profit margins, and future P/E expectations.
Narrative Update • Mar 19

LFVN: Share Repurchases And Stable Margins Will Support Future Upside Potential

Analysts have trimmed their $7.00 price target on LifeVantage, citing updated fair value, discount rate, revenue, margin, and future P/E assumptions that now point to a more measured risk and return profile for the stock. Analyst Commentary Analysts cutting their $7.00 price target are largely reacting to updated views on fair value, discount rate, revenue, margins, and future P/E assumptions, which together frame a more balanced outlook for LifeVantage.
Narrative Update • Mar 05

LFVN: Buybacks And Margin Improvement Will Support Future Upside Potential

Narrative Update on LifeVantage Analysts have lowered their price target on LifeVantage by $7, citing updated assumptions for the discount rate, revenue trajectory, profit margin and future P/E, which together indicate a more cautious valuation framework. Analyst Commentary Analysts describe the lower price target as a reset of expectations rather than a change in the core story, anchoring their work in updated views on discount rate, revenue trajectory, profit margin and future P/E.
Narrative Update • Feb 18

LFVN: Higher Future P/E And Buybacks Will Support Confident Upside Potential

Analysts have reduced their price target on LifeVantage from $14.50 to $8.00, citing updated assumptions for revenue trends, profit margins, and a slightly adjusted discount rate, even as they apply a somewhat higher future P/E multiple. Analyst Commentary Analysts cutting the price target to $8.00 are recalibrating how they see LifeVantage balancing execution risk with potential upside in its valuation.
Analysis Article • Feb 06

Investors Give LifeVantage Corporation (NASDAQ:LFVN) Shares A 26% Hiding

Unfortunately for some shareholders, the LifeVantage Corporation ( NASDAQ:LFVN ) share price has dived 26% in the last...
Narrative Update • Feb 04

LFVN: Gut Health Research Progress Will Support Confident Upside Potential

Analysts are keeping their price target for LifeVantage steady at US$14.50, indicating only very small adjustments in their discount rate and long term assumptions such as revenue growth, profit margin and future P/E that do not materially change their overall view. What's in the News LifeVantage announced new in vitro study results for its proprietary P84 formula, showing strong biological activity in cellular pathways linked to gut regulation, repair, and restoration across four gut cell types (Key Developments).
Narrative Update • Jan 21

LFVN: Gut Study Advances And Guidance Confidence Will Support Future Upside Potential

Analysts have kept their price target for LifeVantage unchanged at $14.50, reflecting only minor tweaks to assumptions around discount rate, revenue growth, profit margin and future P/E, rather than a shift in their overall view of the stock. What's in the News LifeVantage reported new in vitro study results for its proprietary P84 formula, showing strong biological activity in cellular pathways tied to gut regulation, repair, and restoration across four gut cell types, with all 14 analyzed peptides and proteins moving in the intended direction in a controlled, third party study (Key Developments).
Narrative Update • Jan 07

LFVN: Gut Study Progress Will Drive Future Upside Potential

Analysts have slightly adjusted their price target for LifeVantage to $14.50, reflecting small tweaks to assumptions around the discount rate, long term revenue growth, profit margin, and future P/E used in their valuation models. What's in the News LifeVantage reported new in vitro study results for its proprietary P84 formula, with all 14 analyzed gut-related peptides and proteins moving in the desired direction in a controlled, third-party study across four gut cell types (Key Developments).
Narrative Update • Dec 22

LFVN: Future Gut Health Research And Buybacks Will Drive Upside

Analysts have modestly raised their price target on LifeVantage to 14.50 dollars from 14.50 dollars, citing largely unchanged expectations for fair value, discount rate, revenue growth, profit margins, and future valuation multiples that together reinforce a stable outlook for the shares. What's in the News New in vitro study of LifeVantage's P84 gut health formula showed strong biological activity across 14 key gut peptides and proteins, with several biomarkers increasing well above the 20 to 30 percent threshold typically considered meaningful in controlled cellular research (Key Developments) Key P84 results included a 1,087 percent increase in gastrin releasing peptide, a 116 percent increase in trefoil factor 3 for gut lining repair, and a 100 percent increase in vasoactive intestinal peptide that helps calm overactive areas of the gut (Key Developments) LifeVantage plans next phase research using mRNA sequencing to study P84 in combination with its Protandim Nrf2 Synergizer and MindBody GLP 1 System formulas, deepening the scientific backing for its gut and cellular activation portfolio (Key Developments) LifeVantage reported it has repurchased a cumulative 5,068,960 shares, or 37.65 percent of its outstanding stock, for 43.27 million dollars under a buyback program initiated in 2017, including 44,364 shares in the most recent quarter (Key Developments) The company reiterated fiscal 2026 guidance, expecting full year revenue between 225 million and 240 million dollars and forecasting second half revenue to exceed the first half, supported by MindBody product seasonality and the LoveBiome acquisition (Key Developments) Valuation Changes Fair Value Estimate: unchanged at 14.50 dollars per share, indicating no material shift in the intrinsic value assessment.
Narrative Update • Dec 08

LFVN: Future Index Inclusion Will Drive Upside Potential

Analysts have modestly raised their price target on LifeVantage to approximately $14.50 per share, reflecting slightly updated assumptions for discount rates, long term revenue growth, and profitability, while maintaining a broadly unchanged fair value outlook. What's in the News New in vitro study of LifeVantage’s proprietary P84 gut health formula showed strong biological activity across 14 key gut peptides and proteins, with several markers, including GRP, TFF3, VIP, and OXM, demonstrating notably large increases in levels, supporting the scientific rationale behind the product portfolio expansion (company study announcement).
Narrative Update • Nov 24

LFVN: Share Repurchases and New Index Addition Will Drive Value

LifeVantage Analyst Price Target Revised Downward Amid Softer Growth Expectations Analysts have lowered their price target for LifeVantage from $18.00 to $14.50. They cite reduced projections for revenue growth and profit margins as key factors in their updated assessment.
Analysis Article • Nov 14

Lacklustre Performance Is Driving LifeVantage Corporation's (NASDAQ:LFVN) 28% Price Drop

Unfortunately for some shareholders, the LifeVantage Corporation ( NASDAQ:LFVN ) share price has dived 28% in the last...
Analysis Article • Nov 04

We Ran A Stock Scan For Earnings Growth And LifeVantage (NASDAQ:LFVN) Passed With Ease

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Analysis Article • Sep 30

It's Down 25% But LifeVantage Corporation (NASDAQ:LFVN) Could Be Riskier Than It Looks

LifeVantage Corporation ( NASDAQ:LFVN ) shareholders that were waiting for something to happen have been dealt a blow...
Analysis Article • Sep 05

LifeVantage (NASDAQ:LFVN) Will Pay A Dividend Of $0.045

The board of LifeVantage Corporation ( NASDAQ:LFVN ) has announced that it will pay a dividend on the 16th of...
Seeking Alpha • Jul 21

The LifeVantage Advantage: High Retention, High Returns

Summary LifeVantage leads in nutrigenomics, focusing on how nutrition impacts gene expression for optimal health. LifeVantage projections indicate a strong 26.6% EPS CAGR through 2027, driven by high-margin products, cost controls, and a shift toward long-term wellness-focused consultant strategies. The MindBody GLP-1 System now accounts for most of LFVN’s growth, with 85% of new users on monthly subscriptions, creating a reliable and recurring revenue stream. Shares trade at a discounted 15.6x forward P/E, below the staples sector median and peers like Nature’s Sunshine, offering valuation upside, alongside dividend yield and liquidity strength. Risks include heavy reliance on one product and retention uncertainty, as subscription fatigue, or competitive GLP-1 alternatives could weaken revenue durability and challenge the bullish case. Read the full article on Seeking Alpha
Analysis Article • May 13

Shareholders Can Be Confident That LifeVantage's (NASDAQ:LFVN) Earnings Are High Quality

When companies post strong earnings, the stock generally performs well, just like LifeVantage Corporation's...
Analysis Article • May 02

What You Can Learn From LifeVantage Corporation's (NASDAQ:LFVN) P/E After Its 26% Share Price Crash

To the annoyance of some shareholders, LifeVantage Corporation ( NASDAQ:LFVN ) shares are down a considerable 26% in...

Earnings and Revenue Growth Forecasts

NasdaqCM:LFVN - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/20281654N/AN/A1
6/30/2027178511163
6/30/202618457153
3/31/2026195647N/A
12/31/2025210824N/A
9/30/202522910910N/A
6/30/2025229101112N/A
3/31/202522291213N/A
12/31/202421271314N/A
9/30/2024196457N/A
6/30/202420031012N/A
3/31/202420541113N/A
12/31/202321131114N/A
9/30/20232133913N/A
6/30/2023213347N/A
3/31/2023210-136N/A
12/31/2022206-113N/A
9/30/2022205046N/A
6/30/2022206368N/A
3/31/202221091214N/A
12/31/2021212101316N/A
9/30/2021219141518N/A
6/30/2021220131316N/A
3/31/2021225121317N/A
12/31/2020229121517N/A
9/30/2020232121821N/A
6/30/2020233121618N/A
3/31/2020230121316N/A
12/31/201923012N/A17N/A
9/30/20192278N/A12N/A
6/30/20192267N/A18N/A
3/31/20192247N/A16N/A
12/31/20182186N/A16N/A
9/30/20182106N/A13N/A
6/30/20182036N/A13N/A
3/31/20182003N/A10N/A
12/31/20171941N/A6N/A
9/30/20171941N/A6N/A
6/30/20171992N/A7N/A
3/31/20172024N/A4N/A
12/31/20162135N/A3N/A
9/30/20162166N/A6N/A
6/30/20162076N/A6N/A
3/31/20161994N/A10N/A
12/31/20151883N/A14N/A
9/30/20151843N/A11N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: LFVN's earnings are forecast to decline over the next 3 years (-10.7% per year).

Earnings vs Market: LFVN's earnings are forecast to decline over the next 3 years (-10.7% per year).

High Growth Earnings: LFVN's earnings are forecast to decline over the next 3 years.

Revenue vs Market: LFVN's revenue is expected to decline over the next 3 years (-6.4% per year).

High Growth Revenue: LFVN's revenue is forecast to decline over the next 3 years (-6.4% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if LFVN's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/03 01:42
End of Day Share Price 2026/07/02 00:00
Earnings2026/03/31
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

LifeVantage Corporation is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ilya ZubkovFreedom Broker
Mitchell PinheiroImperial Capital
Ryan MeyersLake Street Capital Markets, LLC